Clinical trial
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic…
NCT00386152 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Terminated
Key facts
| NCT number | NCT00386152 |
|---|---|
| Title | A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy |
| Official title | A Randomized, Open-Label, Comparative Study of Epoetin Alfa (PROCRIT) 80,000 Units or 120,000 Units Q3W (Every 3 Weeks) Versus Darbepoetin Alfa (ARANESP) 500 Mcg Q3W in Anemic Cancer Subjects Receiving Chemotherapy |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Clinical Affairs, L.L.C. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Anemia, Cancer |
| Intervention type | Drug |
| Interventions | epoetin alfa, darbepoetin alfa |
| Enrollment | 235 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Oct 11, 2006 |
| Last update posted | Jul 19, 2013 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: